News articles about Acasti Pharma (NASDAQ:ACST) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Acasti Pharma earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0091899549729 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Acasti Pharma (NASDAQ:ACST) opened at C$1.31 on Friday. Acasti Pharma has a fifty-two week low of C$1.11 and a fifty-two week high of C$2.46.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/acasti-pharma-acst-earning-somewhat-positive-news-coverage-study-shows/1697075.html.

Acasti Pharma Company Profile

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Insider Buying and Selling by Quarter for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.